Advisors Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.48M | Sell |
|
|||||
|
2025
Q1 | $1.58M | Buy |
|
|||||
|
2024
Q4 | $1.33M | Buy |
|
|||||
|
2024
Q3 | $1.31M | Buy |
|
|||||
|
2024
Q2 | $1.11M | Buy |
|
|||||
|
2024
Q1 | $603K | Buy |
|
|||||
|
2023
Q4 | $263K | Buy |
|
|||||
|
2023
Q3 | $229K | Buy |
|
|||||
|
2023
Q2 | $174K | Sell |
|
|||||
|
2023
Q1 | $191K | Sell |
|
|||||
|
2022
Q4 | $227K | Sell |
|
|||||
|
2022
Q3 | $477K | Sell |
|
|||||
|
2022
Q2 | $416K | Sell |
|
|||||
|
2022
Q1 | $643K | Buy |
|
|||||
|
2021
Q4 | $618K | Sell |
|
|||||
|
2021
Q3 | $697K | Buy |
|
|||||
|
2021
Q2 | $625K | Sell |
|
|||||
|
2021
Q1 | $694K | Buy |
|
|||||
|
2020
Q4 | $590K | Buy |
|
|||||
|
2020
Q3 | $561K | Sell |
|
|||||
|
2020
Q2 | $655K | Sell |
|
|||||
|
2020
Q1 | $557K | Sell |
|
|||||
|
2019
Q4 | $926K | Buy |
|
|||||
|
2019
Q3 | $530K | Sell |
|
|||||
|
2019
Q2 | $1.02M | Sell |
|
|||||
|
2019
Q1 | $1.65M | Sell |
|
|||||
|
2018
Q4 | $1.3M | Buy |
|
|||||
|
2018
Q3 | $1.55M | Buy |
|
|||||
|
2018
Q2 | $1.67M | Buy |
|
|||||
|
2018
Q1 | $1.77M | Buy |
|
|||||
|
2017
Q4 | $1.78M | Buy |
|
|||||
|
2017
Q3 | $1.52M | Buy |
|
|||||
|
2017
Q2 | $688K | Sell |
|
|||||
|
2017
Q1 | $487K | Sell |
|
|||||
|
2016
Q4 | $858K | Sell |
|
|||||
|
2016
Q3 | $1.78M | Sell |
|
|||||
|
2016
Q2 | $2.67M | Sell |
|
|||||
|
2016
Q1 | $3.32M | Sell |
|
|||||
|
2015
Q4 | $6.1M | Buy |
|
|||||
|
2015
Q3 | $5.19M | Buy |
|
|||||
|
2015
Q2 | $6.58M | Buy |
|
|||||
|
2015
Q1 | $4.87M | Buy |
|
|||||
|
2014
Q4 | $3.18M | Buy |
|
|||||
|
2014
Q3 | $1.8M | Buy |
|
|||||
|
2014
Q2 | $816K | Buy |
|
|||||
|
2014
Q1 | $332K | Buy |
|